Q1 EPS Forecast for Lexaria Bioscience Decreased by Analyst

Lexaria Bioscience Corp. (NASDAQ:LEXXFree Report) – Research analysts at HC Wainwright dropped their Q1 2025 earnings estimates for Lexaria Bioscience in a research report issued on Monday, December 2nd. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.12) for the quarter, down from their previous estimate of ($0.08). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.34) per share. HC Wainwright also issued estimates for Lexaria Bioscience’s Q2 2025 earnings at ($0.11) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.11) EPS and FY2025 earnings at ($0.46) EPS.

Lexaria Bioscience Price Performance

NASDAQ LEXX opened at $2.59 on Wednesday. The company’s fifty day moving average is $2.57 and its two-hundred day moving average is $2.97. Lexaria Bioscience has a 52-week low of $1.20 and a 52-week high of $6.85. The firm has a market capitalization of $45.20 million, a price-to-earnings ratio of -5.74 and a beta of 0.99.

Insider Buying and Selling at Lexaria Bioscience

In related news, CEO Richard Christopher acquired 22,828 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was purchased at an average cost of $2.24 per share, for a total transaction of $51,134.72. Following the completion of the purchase, the chief executive officer now directly owns 22,828 shares of the company’s stock, valued at $51,134.72. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Lexaria Bioscience

Several large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new stake in Lexaria Bioscience during the second quarter worth about $63,000. Armistice Capital LLC acquired a new position in shares of Lexaria Bioscience in the 2nd quarter worth approximately $2,836,000. Geode Capital Management LLC grew its position in Lexaria Bioscience by 31.0% during the 3rd quarter. Geode Capital Management LLC now owns 150,391 shares of the company’s stock worth $459,000 after acquiring an additional 35,608 shares during the last quarter. HighTower Advisors LLC acquired a new stake in Lexaria Bioscience during the 3rd quarter valued at $40,000. Finally, XTX Topco Ltd raised its position in Lexaria Bioscience by 47.8% in the 3rd quarter. XTX Topco Ltd now owns 18,626 shares of the company’s stock valued at $57,000 after purchasing an additional 6,024 shares during the last quarter. Institutional investors own 13.06% of the company’s stock.

Lexaria Bioscience Company Profile

(Get Free Report)

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.

Recommended Stories

Earnings History and Estimates for Lexaria Bioscience (NASDAQ:LEXX)

Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.